pSivida Announces Future Out-licensing of BioSilicon in Tissue Engineering and Orthopedics; pSivida signs agreement with US based PureTech Development LLC.

PERTH, Australia -- Global nanotechnology company pSivida Limited (Nasdaq:PSDV) (ASX:PSD) (Xetra:PSI) today announced it has signed an agreement with US based PureTech Development LLC ("PureTech") to investigate and evaluate out-licensing opportunities for BioSilicon(TM) with an emphasis on tissue engineering, wound management and orthopedics.

Through a range of collaborative partnerships and internal R&D over the last four years, pSivida has developed the BioSilicon(TM) (nano-structured porous elemental silicon) technology platform in non-core areas such as tissue engineering, wound management and orthopedics to a point where it is in a position and in line with the Company's broader commercialization strategy, to seek suitable partners in these specialist areas of healthcare.

pSivida has commissioned PureTech to explore with suitable partners, arrangements for evaluating the potential of BioSilicon(TM) in their areas of expertise and such partnerships would be expected to produce, in due course, revenue in the form of upfront and milestone payments as BioSilicon(TM) based products are developed and commercialized.

pSivida's core focus remains the development and commercialization of BioSilicon(TM) for controlled release drug delivery.

PureTech Development is a Boston based organization with affiliates in key global life science markets providing transaction advisory services to leading life science companies. Its focus is in market entry strategic planning, R&D collaborations, in/out licensing agreements, distribution channel development, equity investments and M&A. For more information visit www.puretechdevelopment.com.

As a new and unique biomaterial BioSilicon(TM) exhibits many properties that make it an ideal material in which to develop products in these growing areas of healthcare:

--biocompatible, biodegradable semiconductor

--abundant, low cost material

--scale up and manufacture proven over 40 years in the electronics industry

--micromachineable -- nm(10(-9)) sized for biodegradability and um for tissue engineering

--honeycomb structure mimics porous scaffolds found in nature

--natural by-product, dissolves in the body to become silicic acid, the dietary form of silicon found in everyday foods such as beer, rice and wine.

When utilized in tissue engineering BioSilicon(TM) can act as a 'scaffold' to provide tissue cells with a structure to which cells can anchor and penetrate. As the tissue deposits itself onto the scaffold the porous silicon slowly dissolves away leaving just the new tissue. The silicon dissolves to form silicic acid, the most common form of which is found in everyday foods.

In wound management potential products include drug eluting biodegradable BioSilicon(TM) based dressings and sutures. Importantly as BioSilicon(TM) retains the semi-conductor properties of silicon thus, electro stimulation can also be incorporated to enhance the healing process.

In orthopedics a range of BioSilicon(TM) and composite devices are being considered including screws, braces, pins and staples for reconstructive orthopaedic surgery.

pSivida Limited

pSivida is a global nanotechnology company committed to the biomedical sector and the development of products in healthcare. The company's focus is the development and commercialisation of a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon(TM). As a new and exciting biocompatible material, BioSilicon(TM) offers multiple potential applications across the high growth healthcare sector, including controlled release drug delivery, targeted cancer therapies (including brachytherapy and localized chemotherapy), tissue engineering and orthopedics. Potential diagnostics applications are being developed through its subsidiary AION Diagnostics Limited.

For more information visit www.psivida.com

This document contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors including: our failure to develop applications for BioSilicon(TM) due to regulatory, scientific or other issues. Other reasons are contained in cautionary statements in the Registration Statement on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to update any oral or written forward-looking statements that may be made by or on behalf of pSivida.